American Heart Association (AHA): Scientific Sessions 2025 Highlights

The American Heart Association (AHA) Scientific Sessions is an annual, four-day conference that brings together cardiovascular healthcare professionals from around the world to share the latest advances, research, and guidelines in heart and vascular medicine.

AHA 2025 took place in New Orlkeans, Louisiana, between 7-10 November 2025.

GlobalData's cardiovascular & metabolic team attended industry-sponsored and scientific sessions where key therapies were featured, the contents of which were analyzed to create this AHA 2025 Highlights report.

Scope

Indications, companies, and therapies discussed -

GLP-1RAs

• Novo Nordisk - Semaglutide
• Viking Therapeutics - VK2735

Hyperlipidemia

• SHR-1918

Heart Failure

• BacNav

Pulmonary Arterial Hypertension

• Satralizumab

And more!

Reasons to Buy

This Pdf deliverable provides analysis on key presentations from the conference, and what they mean for your strategy, covering disease areas such as Obesity, Heart Failure, Pulmonary Arterial Hypertension, Dyslipidemia, and more.

Inside the report you'll find -

• Emerging trends in cardiovascular and metabolic indications
• Insights into the disease areas that took precedence at the conference
• Key takeaways from headline sessions and late-breaking data
• Clinical and commercial implications of notable presentations